Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
FMR LLC reported beneficial ownership of 8,908,979.89 shares of Dyne Therapeutics common stock, representing 5.4% of the class as of 03/31/2026. The filing shows sole voting power of 8,900,472 shares and sole dispositive power of 8,908,979.89 shares, and references a 13d-1(k) agreement in Exhibit 99.
Dyne Therapeutics, Inc. director-associated investment funds reported open-market sales of an aggregate 227,337 shares of Common Stock on April 28, 2026. The trades were executed at weighted-average prices around $18.38–$19.00 per share under a pre-arranged Rule 10b5-1 trading plan.
The shares are held through Atlas Venture-affiliated funds and partnerships, and the reporting person disclaims Section 16 beneficial ownership beyond any pecuniary interest. Following these transactions, the entities continue to hold large positions, including 4,939,489 shares in one fund and other seven-figure stakes in additional Atlas vehicles.